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Abstract Plasminogen activator inhibitor 1 (PAI-1), a member 
of the serpins, has a unique conformational flexibility. A typical 
characteristic is its intrinsic lability resulting in the conversion of 
the active conformation to a latent conformation. In the present 
study, we have evaluated the effect of substitution of positively 
charged residues located at the turn connecting strand s4C with 
strand s3C, either with negatively charged or with neutral 
residues, on the functional stability of PAI-1. The following 
mutants were constructed, purified and characterized in compar-
ison to wild-type (wt) PAI-1: PAI-1-R186E,R187E (Arg1 8 6^ 
Glu and Arg187 ^ Glu), PAI-1-H190E,K191E (His190-> Glu 
and Lys191 -> Glu) and PAI-1-H190L,K191L (His190 -> Leu and 
Lys191 -»Leu). In contrast to wtPAI-1 the mutants exhibited no 
inhibitory activity. Whereas latent wtPAI-1 can be reactivated 
(up to a specific activity of 78 ± 19%) by treatment with 
guanidinium chloride, a similar treatment applied to these 
mutants resulted in a significant but relatively small increase of 
specific activity (i.e. to 14%). Evaluation of the functional 
stability (at 37°C, pH 5.5, 1 M NaCl) revealed a strongly 
decreased functional stability compared to wtPAI-1 (i.e. 3-9 h 
for the mutants vs. > 24 h for wtPAI-1). Further characteriza-
tion by heat denaturation studies and plasmin susceptibility 
confirmed that removal or reversal of the positive charge on the 
turn connecting s4C with s3C results in PAI-1 mutants with a 
highly accelerated conversion of active to latent forms. We can 
therefore conclude that the pronounced positive charge in the 
turn connecting s4C with s3C is of the highest importance for the 
functional stability of PAI-1. 
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1. Introduction 
Plasminogen activator inhibitor 1 (PAI-1) is a member of the 
serine proteinase inhibitor (serpin) superfamily. All serpins 
have the same highly ordered tertiary structure consisting of 
three ß-sheets, oc-helices A-I and a reactive site loop (PI 6-
P10') [1,2] that contains the active center (Pl-ΡΓ) that mimics 
the normal substrate of the target proteinase [3]. In PAI-1, the 
Arg346-Met347 bond has been identified as the P l - P l ' bond [4]. 
PAI-1 is synthesized as an active molecule that spontane-
ously converts into a latent conformation. The latent confor-
mation, in which the P l - P l ' bond is not accessible due to the 
insertion of strand s4A into ß-sheet A [5], cannot interact with 
the target proteinases but can be reactivated by denaturants 
such as guanidinium chloride, sodium dodecyl sulfate or urea 
[6]. In addition, a stable non-inhibitory conformation with 
substrate properties has been identified [7-9]. Conformational 
studies [5,7,10-13] and evaluation of the heat denaturation 
properties of the various PAI-1 forms have revealed that the 
differences in functional properties are associated with the 
existence of these different conformations. In addition, con-
trary to the active and the substrate conformations, latent 
PAI-1 typically contains an exposed plasmin susceptible cleav-
age site resulting in the generation of two degradation prod-
ucts of ~ 2 4 kDa upon incubation with plasmin [14]. 
Comparison of the crystal structure of a cleaved non-inhib-
itory substrate mutant PAI-1-P12 (Ala -»Pro at P12) [15] with 
that of latent PAI-1 [5] revealed major positional differences 
among loop 1 (His185-Pro200, the turn connecting strand s4C 
with strand s3C) and loop 2 (Glu242-Pro246, the turn connect-
ing strand s3B with helix hG) [15]. From this comparison it 
was also deduced that the mobility of 'loop Γ is required for 
transition to the latent form [15,16] and it was subsequently 
hypothesized that the presence of positively charged residues 
in this region (i.e. Arg186, Arg187, His190 and Lys191) plays a 
critical role in the functional stability of PAI-1. In the present 
study, we describe the characterization of three mutants of 
PAI-1 in which the following mutations were introduced: 
Arg186 -»Glu and Arg187 -»Glu (PAI-1-R186E.R187E); 
His190 -> Glu and Lys191 -> Glu (PAI-1-H190E,K191E), His190-
-^Leu and Lys191 -> Leu (PAI-1-H190L,K191L). Comparison 
of the properties of these mutants with those of wtPAI-1 
demonstrated that this positively charged region is of the ut-
most importance for the stability of PAI-1. 
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2. Materials and methods 
2.1. Materials 
Restriction enzymes were obtained from Pharmacia (Uppsala, Swe-
den) or from Boehringer Mannheim (Brussels, Belgium). T4 DNA 
ligase, the Klenow fragment of Escherichia coli DNA polymerase I 
and alkaline phosphatase were purchased from Boehringer Mannheim 
(Brussels, Belgium). M13K07 helper phage was obtained from Prom-
ega (Leiden, The Netherlands). The expression vector pIGE20 was 
kindly provided by Innogenetics (Ghent, Belgium), together with the 
bacterial strains E. coli DHIX for cloning and E. coli MC1061 for 
0014-5793/97/S17.00 © 1997 Federation of European Biochemical Societies. All rights reserved. 
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expression as well as the pAcI plasmid encoding the thermolabile 
repressor. 
The chromogenic substrate S-2403 was obtained from Chromogenix 
(Mölndal, Sweden). t-PA (predominantly single-chain) was a kind gift 
from Boehringer Ingelheim (Brussels, Belgium); single-chain u-PA 
(scu-PA) from which low molecular weight two-chain u-PA (tcu-
PA) was prepared and plasmin were kindly provided by Dr. Lijnen 
(University of Leuven, Belgium). 
2.2. Construction, expression and purification of PAI-1 and PAI-1 
mutants 
In vitro site-directed mutagenesis of PAI-1 was performed as de-
scribed earlier [17] using the pMa/c system ([18], kindly provided by 
Corvas, Ghent, Belgium) and the following synthetic oligonucleotides 
to obtain the desired mutation: PAI-1-R186E,R187E, 5'-GA TTT 
GTG GAA GAG CTC TTC GTG GGT GCT GGA G-3'; PAI-1 -
H190E,K191E, 5'-CT GCC GTC TGA TTC TTC GAA GAG GCG 
GCG-3'; PAI-1-H190L,K191L, 5'-GT GCT GCC GTC ACT TAA 
GAG GAA GAG GCG G-3'. Specific restriction sites, i.e. a Sad site 
(GAGCT1C) and a Banll site (G(A,G)GC(C,T) ¿ C) for PAI-1-
R186E,R187E; a NspV site (TTJ.CGAA) for PAI-1-H190E,K191E; 
a Aflll site (CJ.TTAAG) for PAI-1-H190L,K191L were simultane-
ously created to allow confirmation of the desired mutation by re-
striction analysis. Sacl-Xbal fragments from pMa-PAI-1-
H190E,K191E and pMa-PAI-l-H190L,K191L and Stul-Xbal frag-
ments from the mutant pMa-PAI-l-R186E,R187E were recovered 
and substituted for the Sacl-Xbal and Stul-Xbal fragments, respec-
tively, in pIGE20-wtPAI-l. Nucleotide sequencing using A.L.F. 
(Pharmacia) was used to confirm the presence of the desired mutation. 
Expression and purification of wtPAI-1 and PAI-1 mutants was per-
formed in E. coli as described earlier [14]. 
2.3. Immunological and functional determination of PAI-1 
Comparative reactivity between the mutants and active and latent 
forms of wtPAI-1 was evaluated in an ELISA MA-19A6/MA-9E4-
HRP exclusively sensitive to active and substrate PAI-1 [19]. PAI-1 
activity was determined using the method described by Verheijen [20], 
All PAI-1 activity data are expressed as percentage of the theoretical 
maximum activity, i.e. ~ 745 000 U/mg (t-PA inhibitory units) and 
120000 U/mg (u-PA inhibitory units) [14]. 
2.4. Conformational distribution of PAI-1 mutants 
PAI-1 samples were diluted with phosphate buffered saline (PBS) to 
a concentration of 0.3 mg/ml and incubated for 30 min at 37°C with a 
two-fold molar excess of t-PA, u-PA or plasmin. The reaction was 
terminated by adding SDS (final concentration 1%) and heating for 30 
s at 100°C. Reaction products were analyzed by sodium dodecyl sul-
phate-polyacrylamide gel electrophoresis (SDS-PAGE) using 10-15% 
gradient gels under non-reducing conditions with the Phast System 
(Pharmacia, Uppsala, Sweden). Proteins were visualized by staining 
with Coomassie brilliant blue and quantified by densitometric scan-
ning with the Imagemaster (Pharmacia). 
2.5. Determination of the stability of the reactivated wtPAI-1 and 
PAI-1 mutants 
PAI-1 samples were diluted to 20 μg/ml in PBS containing 2 mM 
glutathione and 0.01% Tween 80 and incubated with 6 M guanidi-
nium chloride for 25 min at 37°C, followed by extensive dialysis at 
4°C against 50 mM sodium acetate buffer, pH 5.5, containing 1 M 
NaCl, 2 mM glutathione and 0.01% Tween 80 [21]. Reactivated PAI-1 
samples were subsequently incubated at 37°C and aliquots were re-
moved at various times and assayed for inhibitory activity against 
t-PA and u-PA. 
2.6. Heat denaturation studies of wtPAI-1, PAI-1 mutants and 
derivatives 
Samples containing latent PAI-1 or PAI-1 mutants were diluted to 
20 μg/ml in 20 mM sodium acetate buffer pH 5.5 containing 1 M 
NaCl and 0.01% Tween 80 and incubated at a constant temperature 
between 30°C and 100°C for 2 ho. The samples were then cooled in 
ice and centrifuged for 15 min in a microfuge at 14000 rpm to remove 
precipitated protein. The supernatants were carefully removed and 
either analyzed immediately or stored at —20°C. Residual PAI-1 pro-
tein in the supernatant was determined using the MA-15H12/MA-
12A4 ELISA [22] and is expressed as percentage versus the initial 
value. The Tm50% value is the temperature at which 50% of the anti-
gen is precipitated. 
2.7. Statistical analysis 
The statistical significance of differences was evaluated using Stu-
dent's i-test; P-values <0.05 were considered significant. 
3. Results 
3.1. Determination of specific inhibitory activity against t-PA 
and u-PA 
wtPAI-1 had a specific activity of 77 ±14% (mean ± S.D., 
n = 6) of the theoretical maximum value towards t-PA. In 
contrast, PAI-1-R186E,R187E, PAI-1-H190E,K191E and 
PAI-1-H190L,K191L did not exhibit inhibitory activity 
(<2%) towards t-PA or u-PA (Table 1). After inactivation 
followed by reactivation using guanidinium chloride, wtPAI-1 
could be reactivated up to 78 ±19% (towards t-PA) whereas 
under these conditions PAI-1-R186E,R187E, PAI-1-
H190E,K191E and PAI-1-H190L,K191L were reactivated to 
a much lower extent, i.e. 14 ±8%, 1.2 ±0.5% and 12 ±8%, 
respectively, towards t-PA (Table 1). Comparable data were 
obtained towards u-PA. These reactivated PAI-1 mutants re-
vealed, at 37°C in sodium acetate buffer, pH 5.5, containing 1 
M NaCl, half-lives of 9 ± 5 h (PAI-1-R186E,R187E) and 3 ± 3 
h (PAI-1-H190L,K191L) whereas under these conditions 
wtPAI-1 had, as expected, a half-life >24 h. 
3.2. Reaction products formed after incubation ofwtPAI-1 and 
PAI-1 mutants with various serine proteinases 
As expected, incubation of active wtPAI-1 with a two-fold 
molar excess of t-PA revealed the formation of t-PA/PAI-1 
complexes (58±8.6%>, mean ± S.D., w = 4), small amounts of 
cleaved derivative (9.1 ±4.5%) and residual non-reactive ma-
terial (33 ±4.3%) (data not shown). In the presence of a two-
Table 1 
Specific activity towards t-PA (A) and u-PA (B) before and after inactivation at 37°C and after reactivation 
Start Inactive Reactivated 
wtPAI-1 
PAI-1-R186E,R187E 
PAI-1-H190E,K191E 
PAI-1-H190L,K191L 
wtPAI-1 
PAI-1-R186E,R187E 
PAI-1-H190E,K191E 
PAI-1-H190L,K191L 
77 
0.54 
0.1 
1.6 
79 
±14" 
l±0.12 
±0.02 
±0.4 
±16 
0.53 ±0.17 
<0.1 
1.6 ±1.6 
1.6 ±0.75 
0.41 ±0.32 
<0.1 
<0.1 
1.9 ±0.7 
<0.1 
0.11 ±0.14 
<0.1 
78 
14 
±19 
±8 
1.2±0.53 
12 
70 
13 
±8 
±22 
±4.0 
2.3± 1.7 
12 ±6.6 
aExpressed as percentage of the theoretical maximum value; mean± S.D., n = 5-9. 
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fold molar excess of u-PA, wtPAI-1 revealed similar reaction 
products. In contrast PAI-1-R186E,R187E, PAI-1-H190E, 
K191E and PAI-1-H190L,K191L were virtually completely 
non-reactive ( > 96%) towards t-PA as well as towards u-PA 
(Fig. 1), compatible with the absence of inhibitory activity in 
these mutants. 
In the presence of a two-fold molar excess of plasmin, latent 
wtPAI-1 revealed the formation of two degradation products 
migrating with a molecular weight of approximately 24 kDa 
(Fig. 1). Under these conditions also PAI-1-R186E,R187E, 
PAI-1-H190E,K191E and PAI-1-H190L,K191L revealed the 
generation of two degradation products of 24 kDa (Fig. 1). 
3.3. Recognition in 19A6I9E4 ELISA 
Active wtPAI-1, latent wtPAI-1, PAI-1-R186E,R187E, 
PAI-1-H190E,K191E, and PAI-1-H190L,K191L were applied 
on the MA-19A6/MA-9E4-HRP ELISA. The relative reactiv-
ities of the mutants compared to active PAI-1 were 2 ± 2% for 
latent PAI-1, <0.15% for PAI-1-R186E,R187E, 0.4 ±0.3% 
for PAI-1-H190E,K191E, and 0.9 ±0.6% for PAI-1-
H190L,K191L. 
3.4. Heat-induced denaturation of different conformations of 
wtPAI-1 and PAI-1 mutants 
The heat denaturation profiles of active wtPAI-1, latent 
150-, 
Temperature (° C) 
Fig. 2. Heat denaturation profiles of latent wtPAI-1 and PAI-1 mu-
tants. Active wtPAI-1 (■), latent wtPAI-1 (·), PAI-1-R186E,R187E 
(O), PAI-1-H190E.K191E ( τ ) , PAI-1-H190L,K191L (D). All data 
represent mean ± S.E.M., n = 2-3. 
wtPAI-1, PAI-1-R186E,R187E, PAI-1-H190E,K191E, and 
PAI-1-H190L,K191L are shown in Fig. 2. The Tm50% values 
are 54°C for active wtPAI-1, 86°C for wtPAI-1, 76°C for PAI-
1-H190L,K191L, >90°C for PAI-1-R186E,R187E and PAI-
1-H190E,K191E. 
4. Discussion 
Fig. 1. SDS-PAGE of latent wtPAI-1 and PAI-1 mutants after addi-
tion of a two-fold molar excess of proteinase. Lanes 1-4: latent 
wtPAI-1; 2-8: PAI-1-R186E.R187E; 9-12: PAI-1-H190E,K191E; 
13-16: PAI-1-H190L,K191L. Proteinase: t-PA (lanes 2, 6, 10, 14), 
u-PA (lanes 3, 7, 11, 15), and plasmin (lanes 4, 8, 12, 16). The 
closed arrowhead indicates the migration position of intact PAI-1. 
The open arrowhead indicates the migration position of the cleaved 
substrate form. The arrow indicates the position of the degradation 
products with molecular masses of ~ 24 kDa. 
PAI-1 is unique among the serpins because it is the only 
serpin that, under physiological conditions and also in vivo, 
converts spontaneously and reversibly into a non-reactive, la-
tent conformation [6]. This conversion occurs much more 
slowly at pH 5.5 and at a ionic strength of 1 M NaCl [21]. 
Non-reactive conformations have been induced in antithrom-
bin III [23] and oci-antitrypsin [24] by treatment with 0.9 M 
guanidinium chloride or incubation at 60-70°C. Several stud-
ies on PAI-1 have been described where either site-directed 
mutagenesis or random mutagenesis has led to an increased 
functional stability [14,25-27]. Random mutagenesis suggested 
that only few single amino acid substitutions are capable of 
significantly increasing the stability of PAI-1 [26]. In addition, 
structural studies have shown that the conformational change 
accompanied with the conversion of active to latent serpins 
involves the formation of a central ß-strand s4A by insertion 
of the N-terminal side of the reactive site loop into ß-sheet A 
and a loss of strand slC from sheet C followed by the tran-
sition of the C-terminal side of the reactive site loop through a 
gap composed of two loops [5,15,16,27]. The distance between 
the two loops, i.e. loop 1 (His185-Pro200; connecting strand 
s4C with s3C) and loop 2 (Glu242-Pro246; connecting strand 
s3B with helix hG) was found to be 14 A in the latent con-
formation compared to only 7 A in the reactive conformation. 
This gap widening is primarily due to a positional difference 
of loop 1 [15]. In some studies, it has been suggested that for 
most serpins strand s4C and strand s3C (connected by loop 1) 
is accommodated to a hydrophobic pocket consisting of res-
idues equivalent to Pro276, Phe278, Leu280, Phe358 and Pro379 in 
PAI-1. In contrast, in PAI-1, the C-terminus occupies this 
hydrophobic pocket, which possibly explains the mobility of 
strand s3C and s4C (and loop 1) [5,27]. However, engineering 
a disulfide bond between strand s3C and the C-terminus of 
PAI-1 to reduce the mobility of strands s3C and s4C only 
slightly increased the functional stability of PAI-1 [27]. Alter-
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natively, it has been suggested that an electrostatic repulsion 
between Arg356 (ΡΙΟ') and positively charged residues on loop 
1 (Arg186, Arg187, His190 and Lys191) is in part responsible for 
the repositioning of the loops and consequently for the wid-
ening of the gap resulting in the transition from the active to 
the latent form [15]. 
The current study reveals the importance of the positively 
charged residues at the N-terminal region of 'loop Γ on the 
specific activity and functional stability of PAI-1. Three mu-
tants in which the positively charged residues at the N-termi-
nal region of 'loop Γ were substituted either with negatively 
charged or with neutral residues, i.e. PAI-1-R186E,R187E, 
PAI-1-H190E,K191E and PAI-1-H190L,K191L, revealed a 
lack of inhibitory activity towards t-PA and u-PA. Conforma-
tional distribution analysis confirmed the absence of complex 
formation and revealed the absence of substrate behavior in-
dicating that no interaction occurs between the Pl -Pl ' site of 
the PAI-1 mutants and the target proteinases, compatible with 
the presence of a latent conformation. Indeed, previous stud-
ies [14] have shown that putative plasmin cleavage sites (i.e. 
Lys176-Thr177; Arg187-Leu188; Lys191-Ser192) are exclusively 
present in latent forms of PAI-1 typically resulting in the 
generation of two degradation products with molecular 
masses of 24 kDa upon incubation of latent forms with plas-
min. In the current study all PAI-1 mutants yielded two deg-
radation products of ~ 2 4 kDa upon incubation with plas-
min, in keeping with the occurrence of a latent conformation. 
Alternatively, the occurrence of the latent conformation in 
these inactive mutants was further confirmed by their heat 
denaturation profile which was typically like that observed 
for latent serpins [12,14,23]. In addition, the three mutants 
studied exhibited a very low reactivity in an assay that specif-
ically recognizes active forms of PAI-1. Taken together, these 
four characteristics clearly demonstrate that the non-reactive 
behavior of these mutants is explained by their latency. Con-
sequently, it can be concluded that upon synthesis of these 
mutants the proteins are folded into the active conformation 
(as for wtPAI-1) which is then converted to the latent con-
formation. The latter conversion is strongly enhanced for 
these mutants as compared to that observed with wtPAI-1. 
This hypothesis is further supported by the denaturation/re-
naturation experiments together with functional stability tests. 
These experiments revealed indeed that the inhibitory activity 
can be restored in these mutants but that the active inhibitory 
conformation of these mutants had a much shorter half-life 
compared to that of active wtPAI-1. It is of interest to note 
that the positive charge at positions 187, 190 and 191 in PAI-1 
is fully conserved between various species [28]. However, the 
charge at residue 186 is absent (i.e. replaced by Gin) in rat 
and murine PAI-1. Since rat and murine PAI-1 have similar 
stabilities as human PAI-1, one could speculate that the pos-
itive charge at position 186 has only a minimal, if any, influ-
ence on the stability of PAI-1. 
In conclusion, we have identified a positively charged region 
in PAI-1 (i.e. residues 186, 187, 190 and 191) localized in an 
area previously suggested to play a role in the lability of PAI-
1, that contributes significantly to the functional stability of 
PAI-1. Elucidation of the three-dimensional structure of these 
mutants will allow a detailed evaluation at a molecular level 
of the interactions involved between this region and other 
parts of the molecule. Thus, the current mutants constitute 
useful tools to obtain more insight into the underlying mech-
anisms involved in the conformational transitions in PAI-1. In 
addition, our current observations suggest that loop 1 might 
be a possible target for in vivo modulation of PAI-1 activity 
based on an enhanced conversion to the latent state. This may 
contribute to the development of pharmacological agents for 
the prevention of diseases associated with high PAI-1 levels. 
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